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Introduction
The development of new small-molecule inhibitors for clinical 
anticancer use has gained increased attention because of the cen-
tral role that protein kinases play in cellular proliferation and cell 
division. Many proteins have been identified as potential targets 
of small-molecule inhibition to affect therapeutic intervention, 
including the Rb/CDK4 complex, based on its central role in 
cell cycle regulation,1 components of the PI3Kinase pathway,2 as 
well as the heat shock protein HSP90 in melanoma3 and Poly 
(ADP-ribose) polymerase to sensitize brain tumors to radiation 
treatment.4 However, establishing the bioavailability of new com-
pounds can be confounded by a lack of rapid and robust assays. 
For example, techniques such as radioimmunoassays, binding 
assays5 and HPLC separation6,7 can frequently fail to meet the 
requirements of throughput and accuracy, as they may lack sensi-
tivity or specificity, may not be quantitative or may be time con-
suming. Similarly, documenting in vivo tumor responsiveness is 
often very difficult due to, among other reasons, the anatomic 
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location of the tumor in organs such as the liver, prostate and 
brain, and monitoring surrogate tissues such as peripheral blood 
mononuclear cells does not always reflect antitumor activity.
The purvalanols are members of the 2,6,9-trisubstituted 
purine group of cyclin-dependent kinase (CDK) inhibitors, 
which are generally well tolerated in vivo.8 We have previously 
established that VMY-1-103 (VMY), a dansylated analog of pur-
valanol B (PVB), induced apoptosis at least 10-fold more potently 
in vitro than PVB in human prostate cancer,9 medulloblastoma 
(MB)10 and breast cancer11 cell lines. Dansylation of compounds 
is known for its ability to enhance detection by mass spectrom-
etry,12 suggesting mass spectrometry could be used to evaluate 
the distribution of VMY in both serum and tissue samples when 
administered in vivo.
We have previously described the use of magnetic resonance 
imaging (MRI) and the ND2-SmoA1 preclinical medulloblas-
toma (MB) mouse model for preclinical testing of small-mole-
cule compounds for the treatment of MB,13 and we have used 
anatomical MRI and proton MR-spectroscopy (1H-MRS) to 
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VMY, as predicted (Fig. 1B). The peak intensities of PVB and 
VMY occurred at 7.7 and 8.7 min, respectively. Standard curves 
for VMY and PVB were run on serial dilutions in methanol as 
described in the Methods (Fig. 2). Each standard curve was run 
in triplicate. Both calibration curves showed high linearity with 
VMY having a linear range of 0.00018–14.0 μM and PVB hav-
ing a linear range of 0.0024–2.0 μM with R-squared values of 
0.997 and 0.995, respectively.
The lowest limit of quantitation (LLOQ) was defined as 
the lowest concentration at which the MS signal was equal to 
20 kilocounts, or the signal to noise ratio was greater than 10. 
Using these values and the data from the calibration curves the 
calculated LLOQ values for VMY and PVB were projected to be 
0.15 nM and 2.2 nM, respectively.
We next determined the empirical limit of detection. Limiting 
dilutions of PVB and VMY were performed to define the limits of 
detection for both compounds, and area under the curve analy-
ses (AUC) were performed to quantify the sample. The observed 
LLOQ values of VMY and purvalanol B were 0.18 nM for VMY 
and 2.4 nM for PVB (Fig. 3) and were in agreement with the pro-
jected values of 0.15 nM for VMY and 2.2 nM for PVB. These 
experiments establish that dansylation both increased measure-
ment sensitivity by approximately 15-fold at the lowest limits of 
detection and significantly increased the linear range of VMY 
quantification.
Effects of danyslation on solubility. Having developed an 
accurate and sensitive assay for VMY and PVB, we next addressed 
the effects that danyslation may have on the chemical character-
istics of VMY. We previously established that VMY was signifi-
cantly more effective than PVB in inducing cell cycle arrest and 
apoptosis in cancer cells9-11 and hypothesized that the dansyl mod-
ification increased the VMYs lipophilicity, enhancing its ability to 
traverse the cell membrane. In order to quantify the lipid solubil-
ity of both VMY and PVB, we performed partition coefficient 
measurements, which quantifiy solubility in either an organic or 
aqueous phase. Using phosphate buffered saline and n-octanol 
and applying the LogD formula described in the Methods sec-
tion, the partition coefficients of VMY and PVB at pH 7.4 were 
found to be 2.03 ± 0.02 (n = 3) and 0.15 ± 0.002 (n = 3), respec-
tively, confirming the increased lipophilicity of VMY.
LC-MS/MS detection of VMY in mouse tissue. In order 
to perform calculations of the concentration of VMY or PVB 
contained within tissue fragments, the methodology for, and 
efficiency of, extraction of VMY and PVB from tissue was first 
established. Efficiencies of extraction were modeled by injecting 
1.55 micromoles in 55 microliters of either compound into 108 μg 
fragments of fresh mouse spleen. The tissues were stored on ice 
for 60 min. The fragments were homogenization in water, and 
an organic phase extraction methodology using dichlorometh-
ane (DCM) was developed as described in the Methods section. 
Following the organic phase extraction and separation by centrif-
ugation, the samples were lyophilized, resuspended in methanol 
and quantified by LC-MS/MS as described in the Methods sec-
tion. Using this method, both compounds were equally recovered 
from tissue at an average of 97% efficiency (n = 3, not shown), 
establishing that the different LogD values for VMY and PVB 
follow tumorigenesis in mouse models of prostate,14 breast15 and 
gastric16 cancers. In the present study, we evaluated VMY’s bio-
availability and efficacy in normal and ND2-SmoA1 mice using 
LC-MS/MS and MRI.
Herein, we provide the methodologies necessary to perform 
rapid tissue extraction of VMY and PVB using a phase separation 
technique and coupled this to detection by liquid chromatogra-
phy tandem mass spectrometry (LC-MS/MS). Through apply-
ing area under the curve (AUC) analyses, quantification of VMY 
in target tissues, such as brain, prostate, blood and urine, was also 
achieved. In addition, longitudinal MRI and single voxel proton 
MR-spectroscopy (1H-MRS) enabled an in vivo visualization of 
VMY’s impact on MB, establishing that VMY was able to affect 
changes in tumor metabolism and block disease progression in 
the ND2-SmoA1 medulloblastoma model.
Results
To establish the use of LC-MS/MS as a quantitative method 
for measuring these compounds, direct injections of VMY and 
PVB were performed in the positive mode and yielded a base 
peak of 433.2 m/z (M+1) for PVB, as predicted by the molec-
ular mass (Fig. 1A), and a base peak at 708.3 m/z (M+1) for 
Figure 1. Detection of (A) pVB (433.2 m/z, 7.7 min) and (B) VMY (708.3 
m/z, 8.7 min) by LC-MS/MS in the positive mode.
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amounts of PVB were not detected in the cortex or cerebellum 
(Fig. 5C), VMY at concentrations of 0.14 ± 0.05 uM and 0.53 ± 
0.17 uM were found in the cerebellar and cortical tissue, respec-
tively (Fig. 5C). Similar results were seen for VMY delivery to 
the brain following oral gavage (Fig. S1B).
We have previously used the the ND2-SmoA1 mouse model 
of human medulloblastoma (MB) to establish that subclinical 
doses of the FDA-approved antineoplastic compound arsenic tri-
oxide were effective at treating MB in vivo.13 Since VMY was 
present in the brain of normal mice with intact blood brain bar-
riers (BBB), we investigated whether VMY could be found in the 
tumors of MB-bearing mice, which have a compromised BBB. 
ND2-SmoA1 mice with spontaneous tumors were identified by 
MRI, as previously described,13 and the mice were treated with 
VMY as above. MB samples collected 4 hours after injection had 
an average VMY concentration of 0.5 ± 0.2 uM (Fig. 5C).
VMY decreases tumor growth and metabolism in the 
SmoA1 mouse model of MB. Since VMY was readily detectable 
in MB tumors, we performed longitudinal studies investigating 
the effect of VMY on tumor growth. Once tumors were detected 
by MRI, initial tumor volumes were established by manual seg-
mentation. Animals were randomly chosen for intraperitoneal 
injections with either VMY (20 mg/kg as above) or vehicle (pea-
nut oil), and the treatments performed three times per week for 
up to 12 weeks as an endpoint. There were no significant dif-
ferences in tumor volume at initial diagnosis, (p = 0.20 using a 
one-tailed Mann-Whitney U test, n = 6, Fig. 6A), and no sig-
nificant toxicities were observed during the study. Final tumor 
volumes were established by MRI followed by termination of the 
study. The average tumor volume as established by manual seg-
mentation was 1.46 ± 1.21 mm3 for control and 0.31 ± 0.25 mm3 
for VMY, which is statistically significant (p = 0.03, n = 6 mice 
in each group) using a one-tailed Mann-Whitney U test. The 
do not adversely influence recovery of the compounds from tissue 
using the methods we developed.
For in vivo delivery experiments, mice were injected with 
either vehicle (peanut oil), VMY or PVB at 20 mg/kg. Tissues 
were collected at 1, 4 and 24 h after injection. Venous blood was 
collected from the heart. The excised tissues were weighed on 
an analytical balance, homogenized in water and processed as 
described in the Methods section. As an internal standard, 125 
nanomoles of PVB was added to the VMY samples, followed 
by LC-MS/MS as described. Chromatograms from representa-
tive kidney samples are shown (Fig. 4A). The peak intensities 
occurred at 7.7 min for the PVB internal standard and 8.7 min 
for VMY, as expected. The kinetics and distribution of VMY in 
tissue are shown (Fig. 5). At 1 h post injection, VMY was easily 
detected in prostate, pancreas, fat, urine, serum and spleen. By 
4 h, VMY was detected at its highest levels in these tissues and 
was also found in the kidney (Fig. 5A). At the 24 h time point, 
VMY was detectable in all tissues, except the spleen, at reduced 
levels vs. the 4 h time point (Fig. 5A). VMY was also admin-
istered at 20 mg/kg by oral gavage, and the highest amount of 
VMY was found in the kidney and serum at 1 h, and in the pan-
creas and spleen at 4 h, post-injection (Fig. S1A).
We next investigated the tissue distribution of PVB similarly 
administered at 20 mg/kg via intraperitoneal injection. PVB was 
detected in kidney, spleen, pancreas, prostate lung and serum 
(Fig. 5B). The overall tissue and serum levels of PVB, while lower 
than VMY (note differences in scale), were generally within the 
linear range of detection.
LC-MS/MS detection of VMY in brain tissue. Tissue sam-
ples from the normal cerebellum and cortex were excised from 
mice 4 hours after VMY injection. As with the other tissue 
samples, the brain samples were homogenized in water, extracted 
with DCM and analyzed by LC-MS/MS. While measurable 
Figure 2. Calibration curves. (A) LC-MS/MS calibration curves of pVB (7.7 min) and VMY (8.7 min) at the concentrations shown. (B) Calibration curve 
calculations and R correlation coefficients for VMY and pVB.
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Discussion
The ability to rapidly and accurately quantify the delivery of 
therapeutic compounds to target tissues is an important compo-
nent of drug discovery as well as the preclinical testing of novel 
agents. Unfortunately, the assays used to perform these analyses 
are often complicated, time consuming and, in some cases, indi-
rect. In the present study, we established a simplified methodol-
ogy to quantify, VMY and PVB, members of the trisubstituted 
purine analog family of small-molecule inhibitors, from mouse 
serum. While we have shown that dansylation allows for the in 
vitro identification by fluorescence microscopy of prostate and 
medulloblastoma cells that contain VMY,9,10 this fluorophore 
was insufficient for imaging or quantification of drug delivery 
in vivo (not shown). However, since dansylated compounds are 
readily detectable using mass spectrometry, our expectation was 
that VMY’s dansyl group would enhance our ability to measure 
tissue distribution by LC-MS/MS. VMY’s detection sensitivity 
was increased by nearly 15-fold at the lowest limits of detection, 
and overall sensitivity increased approximately 2-fold vs. PVB.
As shown in Figure 2, PVB and VMY have different col-
umn retention times. We took advantage of this chemical dif-
ference to overcome the need for performing total ion counts for 
quantification of VMY. By using multiple ion trapping, we were 
able to detect PVB and VMY individually in separate channels, 
allowing the use of PVB as an internal standard for VMY tis-
sue quantification. One of the major challenges was developing 
a method to extract the small-molecule inhibitors from various 
tissues, including the blood, without significant sample loss or 
residual tissue fragmentation that could compromise the ability 
to perform spectrometry. We found that an aqueous tissue soni-
fication followed by dichloromethane extraction and phase sepa-
ration centrifugation, a procedure we developed, was superior 
to other methods, such as methanol and acetonitrile extraction 
and syringe-driven filtration (not shown). The dichloromethane 
extraction and centrifugation effectively forced hydrophilic cel-
lular components, including tissue fragments, into the aqueous 
layer, while the hydrophobic VMY and PVB compounds were 
retained in the organic layer, allowing for quick and accurate col-
lection without the need for filtering. In addition, neither VMY 
nor PVB were detected in the aqueous layer (Fig. S3), indicat-
ing that dichloromethane is an appropriate solvent, and extrac-
tion conditions provided for extremely efficient recovery of this 
class of compound. Although dichloromethane can be injected 
directly into the ESI ion trap, we found that evaporation of the 
DCM and resuspension in methanol yielded excellent reproduc-
ibility, possibly due to better ionization by methanol (not shown).
We had previously speculated that VMY’s increased potency 
might be due in part to increased lipid partitioning provided by 
the dansyl group, allowing for better transport across the cell 
membrane.9-11 We now show that VMY is significantly more lipid 
soluble than PVB and, consistent with this, we found VMY at 
higher overall amounts in the blood and tissues, such as prostate, 
which is one of the proposed target organs for VMY therapy. 
In addition, while VMY was consistently found in MB tumor 
samples, as anticipated, VMY was also present in the brain 
overall fold-increase in tumor volume from initial diagnosis to 
study termination was found to be 10.0 ± 3.6 (SEM)-fold in con-
trol animals vs. 3.74 ± 1.45 (SEM)-fold in VMY-treated animals, 
a statistically significant difference (p = 0.014, n = 6). Single voxel 
proton MR-spectroscopy (1H-MRS) was used to interrogate tis-
sue metabolism, as described in the Methods and in previous pub-
lications.14,15 A representative example of voxel placement and the 
resulting 1H-MR spectra is shown (Fig. 6B). The relative ratios 
of tumor metabolites relative to levels of total creatine (Cr) were 
derived following approximately 2 weeks of treatment. Creatine 
levels are relatively constant even under certain pathological 
conditions, and this marker is commonly utilized as an internal 
1H-MRS reference. The 1H-MRS revealed that VMY treatment 
resulted in statistically significant increases in the ratios of Tau 
(taurine, p = 0.024, n = 3) to Cr and mI (myo-inositol, p = 0.024, 
n = 3) to Cr, using one-tailed Mann-Whitney U tests, with little 
to no changes in the Cho (choline) or NAA (N-acetyl-aspartate) 
to Cr ratios (Fig. 6C). Following termination of the study, his-
tological and immunohistochemical analyses revealed an overall 
change in tumor architecture by VMY, including extensive areas 
containing cells with condensed or fragmented nuclei indicating 
cellular necrosis (Fig. S2). Using one-tailed Mann-Whitney U 
tests, VMY was found to induce significant increases in TUNEL-
positive cells (8.9% ± 1.8 for VMY vs. 5.9% ± 0.5 for control, 
p = 0.01, Fig. 6D) and PCNA-positive cells (38.3% ± 12.4 for 
VMY vs. 13.3% ± 12.1 for control, p = 0.025, Fig. 6D), with 
concomitant decreases in nuclear cyclin D1 positivity (13.8% ± 
4.0 for VMY vs. 33.1% ± 4.9 for control, p = 0.024, Fig. 6D). 
These data are consistent with VMY-induced apoptosis and cell 
cycle arrest in G
2
/M17 and consistent with VMY’s effects on cell 
cycle progression and apoptosis in human medulloblastoma cell 
lines in vitro.10
Figure 3. Limits of detection by LC-MS/MS. VMY and pVB at the concen-
trations shown and plotted against count intensities in arbitrary units 
(AU). Data are average ± standard deviation of n = 3 separate experi-
ments. *, p < 0.01 vs. pVB using Student’s t-test’s
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new and existing drugs. Importantly, all of the methodological 
approaches we have described can be easily translated into clini-
cal use, furthering our ability to predict tumor responsiveness in 
vivo and to accurately measure drug delivery and efficacy using 
biopsied tissue.
Methods and Materials
Chemicals. Purvalanol B (P5234) and Octanol (112615) were 
purchased from Sigma-Aldrich. HPLC grade methanol, HPLC 
samples of normal mice with intact BBBs. One of the challenges 
for developing drugs that are meant to target brain malignancies 
is documenting their ability to cross the BBB. Methodologies for 
delivering drugs to the brain have involved intrathecal admin-
istration, convection enhanced delivery via surgically implanted 
catheters, intra-arterial delivery, surgical implantation with drug 
impregnated discs as well as BBB disruptants such as bradykinin, 
mannitol or high intensity focused ultrasound.18-20 More recently 
the BBB has been evaded by activating adenosine receptors,21 fur-
ther underscoring the need for compounds that contain an inher-
ent ability to cross the BBB. Our data establish that delivery of 
purvalanol-based compounds across an intact BBB can be effec-
tuated via dansylation, raising the possibility that similar modi-
fications of other compounds may enhance the rational design of 
brain targeted therapeutics delivered intravenously, orally or via 
other routes, such as intranasal administration. Moreover, dan-
sylation also served as an effective “tag,” greatly increasing the 
measurement of drug via a rapid and sensitive mass spectrom-
etry-based detection method. Such an approach could be use-
ful in future studies, whereby biodistribution and detection are 
enhanced simultaneously with a single modification.
Finally, we have applied MRI and 1H-MRS to non-invasively 
measure tumor responses to VMY. In addition to inhibiting 
tumor growth as measured by segmentation, 1H-MRS established 
that the relative concentrations of taurine and myo-inositol were 
altered in tumors following treatment with VMY. Taurine has 
been found to play a variety of possible roles in the nervous system, 
including affecting osmoregulation, maintaining the integrity of 
the membrane, regulating calcium transport and homeostasis 
and, possibly, functioning as a neuroprotectant.22 The increase in 
Tau seen following VMY treatment may be related to its osmo-
gregulatory role, or perhaps it is in response to the increase in 
overall cellular apoptosis brought about by VMY. Myo-inositol 
is considered a marker of glial cells and changes in the levels of 
mI are associated with white matter diseases and grade II astro-
cytomas.23 Additionally, mI is expected to be altered in response 
to damaged cellular membranes, and increased mI levels are also 
associated with inflammation, and the histological data from the 
mice confirms an increase in inflammation. Other key metabo-
lites were not significantly affected. Choline levels are abundant 
in the MBs of this mouse model,24 and studies have established 
that the levels of choline levels are relatively consistent both in 
brain tumors and in normal brain tissue,25-27 and our data support 
these finding. N-acetylaspartate (NAA) is a marker of neuronal 
metabolism and the relative levels of NAA were unaffected by 
VMY treatment, suggesting that VMY did not have an overall 
adverse effect on the brain, as levels of NAA would be expected 
to change. Based on these data we believe that 1H-MRS may be 
a more sensitive and therefore a more effective early measure of 
drug effectiveness than are changes in overall tumor volume, and 
additional studies are underway to explore this hypothesis.
The development of non-invasive imaging methods to mea-
sure responses to chemotherapy, combined with post-mortem 
data including drug bioavailability, histopathology and molecu-
lar analyses, performed in biologically relevant preclinical mod-
els will enhance our ability to investigate the applicability of 
Figure 4. Measuring VMY or pVB in tissue samples. Representative dual 
ion LC-MS/MS tissue spectra from mice injected with (A) VMY, (B) pVB 
and (C) vehicle (peanut oil).
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SmoA1-ND2 preclinical mouse model. We have recently 
described the use of the ND2-SmoA1 preclinical medulloblas-
toma (MB) mouse model (a generous gift from James Olsen) for 
preclinical testing of small molecule compounds for treatment 
of MB.13 Briefly, this model contains the SmoA1 constitutively 
active point mutation of the Smoothened transmembrane recep-
tor under the control of the NeuroD2 mouse promoter, result-
ing in spontaneous cerebellar medulluloblastoma at 3–4 mo of 
age. Normal, nontransgenic C57Bl6 mice were also used for 
in vivo drug studies. All mice were kept, handled and eutha-
nized in accordance with the Georgetown University Division 
of Comparative Medicine’s ethics guidelines and conditions. 
Mice were genotyped for the SmoA1 transgene as previously 
described.13 VMY or PVB were solubilized in peanut oil and were 
administered at 20 mg/kg. For timepoint studies, mice were sac-
rificed 1 h, 4 h and 24 h after injection. Serum and tissue were 
collected at necropsy. Mice with medulloblastoma were identified 
by MRI as previously reported13 and described below.
MRI. All MRI procedures were performed on the 20 cm bore, 
7T Bruker horizontal magnet running Paravision 5 (Bruker) 
in the Georgetown-Lombardi Preclinical Research Imaging 
Laboratory. Quantitative tumor volumetric analyses were per-
formed essentially as previously described.28 Mice were anesthe-
tized using 1.5% isoflurane and 30% nitrous oxide and positioned 
inside the magnet using a custom-designed animal management 
system with temperature and respiration control,28 which was 
with further adapted to accept a Bruker 4 channel brain array 
coil. The imaging protocol used for anatomical evaluation was a 
T2-weighted RARE (rapid acquisition with relaxation enhance-
ment) with the following parameters: matrix: 256 × 256, TR: 
4660 ms, TE: 36 ms, spatial resolution: 137 μm/pixel and slice 
thickness: 0.5 mm. Quantitative tumor volumetric analyses were 
performed as previously described.14
MRS. Single voxel proton MRS was performed using PRESS 
(Position Resolved Spectroscopy Sequence), essentially as pre-
viously described.14,15 Briefly, parameters of the MRS sequence 
are: TE: 20 ms, TR: 2500 ms, averages: 1,024, spectral width of 
4 kHz, and 2,048 complex data points and 6 Hz line broaden-
ing, using a voxel of 1–2 mm on edge located entirely in tumor 
areas avoiding contamination from normal brain tissue. The 
voxel was positioned using the RARE anatomical image as a 
locator scan. Quantification of neurochemicals was performed 
using the Bruker software program TOPSPIN. When necessary, 
corrections were made for voxel volume related to the size, shape 
and location of the tumor. For comparison of in vivo MRS data, 
creatine was used as the internal standard. Statistical analyses 
grade dichloromethane (DCM), HPLC grade water, phosphate 
buffered saline (PBS) pH 7.4 and formic acid were purchased 
from Fisher Scientific.
VMY-1-103 synthesis and purification. VMY-1-103 was syn-
thesized as previously described. Briefly, starting from commer-
cially available 2-fluoro-6-chloropurine, standard N-9 alkylation 
with 2-propanol under Mitsunobu conditions gave 2-fluoro-
6-chloro-9H-isopropylpurine. The 6-position was substituted 
with dansyl ethylenediamine, followed by substitution at the 
2-position (R)-valinol, yielding VMY-1-103.11
Figure 5. In vivo tissue delivery and quantification. tissue samples 
were collected at the times shown from mice that received intraperi-
toneal injections of (A) 20 mg/kg VMY or (B) 20 mg/kg pVB (note: Y 
axis is micromolar in (A) vs. nanomolar in (B). (C) Brain tissue from mice 
injected with VMY or pVB. All data are average ± standard deviation of 
three separate samples. panc, pancreas; Cb, cerebellum; Ctx, cortex; 
MB, medulloblastoma; N.D., not determinable (below levels of detec-
tion).
Table 1. Liquid chromatography tandem mass spectrometry
Mass spectrometer parameter
Spray chamber temperature 
Nebulizer gas 
Nebulizer pressure 
Drying gas temperature 
Drying gas pressure 
Needle voltage (+) 
Sprayshield voltage (+) 
Data rate
50°C 
Nitrogen 
35 p.s.i. 
350°C 
18 p.s.i. 
5000 V 
600 V 
0.30 Hz
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Autosampler. A Varian Prostar 410 autosampler was used for 
automation purposes. 10–20 μL injections were done using par-
tial loop fill technique for maximum reproducibility.
Sample preparation. Fresh tissue samples were resuspended 
in 80 μL of methanol and transferred to 0.25 mL glass conical 
inserts with poly-support springs (VWR 46610–762) inside of 
Snap-vials (National Scientific) and injected using partial-loop 
uL injection. Standard curves were generated using serial dilu-
tions of stock VMY and PVB made in methanol at concentrations 
of 4, 2, 1, 0.5, 0.25, 0.02 μM, and analyzed by LC-MS/MS using 
the described method above. The R-values for VMY and PVB 
were calculated using GraphPad Prism software by plotting the 
linear regression against the calibration curve intensity values.
Statistical and empirical limit of quantitation (LOQ). Ten blank 
controls with a matrix identical to the experimental samples were 
analyzed by LC-MS/MS, and the mean blank signal value and 
SD were calculated. The statistical LOQ (S
A
)
LOQ
 was calculated 
from the mean blank value plus 10 standard deviations and sum-
marized in the equation below, where (S
A
)
LOQ
 is the signal at the 
limit of quantitation, (S
reag
) is the value of the average blank sig-
nal, σ is the standard deviation, and z is the significance level (set 
to 10 for the strictest criteria). The lowest limit of quantitation 
(LLOQ) is the lowest concentration in the calibration curve at 
which the (S
A
)
LOQ
 signal was equal to 20 kilocounts or the signal 
to noise ratio greater than 10. (SA)
LOQ
 = S
reag
 + zσ
reag
.
were performed using the Mann-Whitney U test due to the 
small sample size, and actual p values are shown. Tissue and 
serum samples were harvested at the termination of the study 
and either immediately fixed in formalin or processed for mass 
spectrometry.
LC-MS/MS detection of compounds. Mass spectrometry. 
Varian workstation software version 6.9.1 was used operate 
the LC-mass spectrometer and autosampler. Drug detection 
and quantification was performed using a Varian 500 ion trap 
LC-MS/MS. Ionization was done using electrospray interface 
(ESI) in the positive mode with operating conditions summa-
rized in Table 1. VMY (exact mass 707.28 amu) was detected 
as an (M+1) ion at 708.35 m/z. PVB (exact mass 432.17) was 
detected as an (M+1) ion at 433.21m/z. Conditions for detection 
of VMY and PVB are summarized in Table 2. Both VMY and 
PVB were detected simultaneously in a single run using two dif-
ferent channels.
Liquid chromatography. Varian 212-LC chromatography 
pumps were used with a Pursuit XRs 3 μm C18 100X2.0mm 
column, Restek Ultra 5 μm 20X2.1 mm guard cartridge. Water 
with 0.1% formic acid and methanol with 0.1% formic acid were 
passed through though pumps A and B, respectively. The pump 
program is summarized in Table 3. Columns were equilibrated 
for 15 min between automated runs with 7 min for ramp and 8 
min for hold which was found to be optimum for this system.
Figure 6. effect of VMY on tumor growth and metabolism. (A) Initial and final tumor volumes as measured by MRI. Data are average ± of either stan-
dard deviation (SD) or standard error of the mean (SeM) of n = 6 mice in each group. (B) Representative voxel placement and in vivo MR-spectral profile 
of MB. (C) effect of VMY on metabolite ratios. Metabolite ratios were established relative to creatine (Cr). (D) tUNeL, pCNA and cyclin D1 immunohis-
tochemical staining of control and VMY-treated MB samples from the mice in (A–C). Abbreviations: mm3, cubic millimeters; Cre, creatine; tau, taurine; 
NAA, N-acetyl-apartate; ppM, parts per million. Data are average ± standard deviation of n = 3 mice asterisk, p < 0.05 using one-tailed Mann Whitney 
U-tests.
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Octanol-PBS partition coefficient (logD). The octanol 
and phosphate-buffered saline (PBS, pH 7.4) partition coef-
ficient (logD) was determined using the traditional shake flask 
method29,30 at 37°C. In a 4 mL vial, 1 mg of each test compound 
was weighed and dissolved in 1 mL of octanol-pre-saturated 
PBS, which was then shaken with 1 mL of PBS-pre-saturated 
octanol for 24 h at 37°C. The velocity of shaking was carefully 
chosen to prevent emulsion formation while allowing thorough 
mixing. After 24 h, the two phases were separated by centrifug-
ing at 10,000 rpm for 10 min, and each layer was transferred 
into separate vials. The individual samples were injected into an 
LC-MS/MS to detect the quantity of the specified compound 
in each layer. The peak intensity value was used to calculate the 
area under the curve (AUC). The partition coefficients at pH 
7.4 (LogD
7.4
) of VMY and PVB were calculated using the AUC 
of the peak intensity and employing the equation: LogD7.4 = 
Log10(AUC
oct
/injection volume of octanol phase) /(AUC
buffer
/
injection volume of buffer phase).
Immunohistochemical staining. Immunohistochemical 
staining was performed on prostate tissue as previously 
described.13,31-34 The slides were blocked for 20 min and incu-
bated overnight at 4°C with the primary antibody. Detection 
was performed as previously described.13,31-34 Because of the small 
sample size statistical analyses were performed using the Mann-
Whitney U test and actual p values are shown.
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Quantification of VMY and PVB. The quantification of 
VMY and PVB in tissue was performed by using Area Under 
the Curve analysis (AUC) by integrating the peak intensity curve 
derived from LC-MS/MS using MS Data Viewer 6.9.1 software 
(Varian, Inc.). For tissue delivery analyses, each VMY sample was 
normalized using the internal standard and the total quantity of 
VMY was calculated by comparing the AUC of each normalized 
sample to the VMY calibration curve. Statistical significances 
calculations were performed using Student’s t-tests
Isolation of VMY and PVB from tissue by phase separa-
tion. VMY or PVB was isolated from tissues using the follow-
ing method. Mouse tissues, removed of any adherent liquid or 
moisture, were weighed on an analytical balance and individu-
ally placed in 2.0 mL Eppendorf tubes. 600 μL of HPLC grade 
distilled deionized H
2
O was added, and the tissues were homog-
enized on ice using an OMNI Tissue Homogenizer (TH-115) 
equipped with two-piece OmniTip (3750H) at 35,000 rpm 
in three 45 sec bursts, incubating the sample on ice for 2 min 
between each burst. Next, 600 μL of HPLC grade dichlorometh-
ane (DCM, Fisher Scientific) was added to the homogenized 
sample, and the tube was vortexed for 1 minute and incubated 
on ice for 2 h. The sample was centrifuged at 14,000 rpm using 
an Eppendorf 5415R refrigerated centrifuge at 4°C for 20 min, 
resulting in a biphasic solution comprised of an aqueous layer 
with tissues debris and a clear DCM layer. The organic layer con-
taining the VMY or PVB and the aqueous phases were collected 
separately in fresh tubes. This extraction process was repeated 
twice by adding an additional 600 μL of DCM to the original 
dH20 and tissue and re-extracting to obtain the maximum recov-
ery. The DCM and aqueous layers from all three extractions were 
lyophilized to dryness and stored at -20°C. A modified proce-
dure was performed to isolate VMY or PVB from the circulation, 
in which 30 μL of serum was aliquoted into 600 μL of HPLC 
grade dH20, and the DCM extraction procedure was performed 
without sonication. To validate that DCM extraction effectively 
extracted VMY and PVB from the tissue and aqueous phase, the 
aqueous fraction was subjected to LC-MS/MS and neither VMY 
nor PVB was found (Fig. S3).
For quantification of VMY across multiple experiments, 125 
nanomoles of PVB was added as an internal standard to each 
sample prior to LC-MS/MS analysis.
Table 2. Mass spectrometry parameters for detecting VMY and pVB
Isolation 
window 
(m/z)
Waveform 
type
Storage 
level 
(m/z)
Excitation 
amplitude 
(m/z)
Ion start 
mass 
(m/z)
Ion end 
mass 
(m/z)
RF 
loading 
(%)
Capillary 
voltage 
(Volts)
High/low 
offset 
(m/z)
Excitation 
time 
(msecs)
Modulate 
Rf
Num 
freq. 
VMY: 3.0 
pVB: 3.0
Resonant 
Resonant
193.1 
129.0
0.0 
0.0
193 
129
711 
436
80 
64
100 
110
0.0 
0.0
30.0 
30.0
Yes 
Yes
0.0 
0.0
Table 3. pump program
Time (min) %A %B Flow rate µl/min Pressure (psi)
0:00 
10:00 
15:00
50 
0.0 
0.0
50 
100 
100
200 
200 
200
2340 
- 
1020
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